Who Buys Bambuterol from India — 7 Importers Behind a $141.2K Market

Our analysis of Bambuterol imports from India between 2022 and 2026 reveals a buyer landscape primarily composed of pharmaceutical distributors. The top two buyers, MYIT MAHAR TRADING CO LTD and MYIT MAHAR TRADING CO., LTD., both based in Myanmar, collectively accounted for 100% of the total import value, amounting to $0.1 million. These entities are indicative of the distributor segment, which typically procures pharmaceuticals in bulk to supply to various healthcare providers, including hospitals, clinics, and pharmacies. Distributors often place large, periodic orders to maintain a steady supply chain and meet the consistent demand from healthcare facilities.

The remaining five buyers, while not individually identified in the provided data, are likely to fall into similar categories, given the nature of pharmaceutical imports. Hospital groups and retail chains may also be involved, procuring Bambuterol directly to ensure availability for patient treatment. Government procurement agencies, such as national health departments or entities like UNICEF, could be potential buyers, especially if Bambuterol is included in national treatment guidelines or essential medicines lists. These segments typically engage in tender-based purchasing, securing large quantities through competitive bidding processes to supply public healthcare institutions. Re-exporters and contract manufacturers are less likely in this context, as the data does not suggest onward export or local production activities related to Bambuterol.

Myanmar:

1. Drug Regulatory Authority Name: Food and Drug Administration (FDA) under the Ministry of Health.

2. Import Registration Process for Bambuterol: Importers must obtain an Import Recommendation from the FDA. All drugs, including Bambuterol, must be registered with the FDA. The registration process involves submitting a drug importation approval certificate, a drug wholesaler's license, and a drug registration certificate. Additionally, an import license from the Ministry of Commerce is required, which may necessitate recommendations from relevant government departments.

3. Estimated Timeline for Registration: The FDA aims to process import recommendations promptly; however, the exact timeline can vary. Import licenses are typically granted within 24 working hours, provided all documentation is in order.

4. Import Tariff/Duty for HS 30049099: The standard import tariff for pharmaceuticals under HS code 30049099 is 3%. However, certain essential medicines are exempt from customs tariffs. As of October 2022, 18 types of imported medicines were granted customs tariff exemption, but Bambuterol was not listed among them. (mdn.gov.mm)

Afghanistan:

1. Drug Regulatory Authority Name: Afghanistan National Medicines and Health Products Regulatory Authority (ANMHRA).

2. Import Registration Process for Bambuterol: Importers are required to register pharmaceuticals with the ANMHRA. The process includes submitting detailed product information, quality certifications, and compliance with national standards. An import license must be obtained, and the importer must hold a valid pharmaceutical business license.

3. Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and the ANMHRA's review procedures.

4. Import Tariff/Duty for HS 30049099: Specific import tariffs for pharmaceuticals under HS code 30049099 are not readily available. Importers should consult the Afghanistan Customs Department for the most current tariff information.

The demand for Bambuterol in Myanmar and Afghanistan is primarily driven by the prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization (WHO), approximately 235 million people worldwide suffer from asthma, with a significant burden in low- and middle-income countries. In Myanmar, Bambuterol is listed in the National List of Essential Medicines (NLEM) as of 2016, indicating its recognized importance in treating respiratory conditions. (platform.who.int)

Government healthcare programs and the expansion of universal health coverage in these countries also contribute to the demand for essential medicines like Bambuterol. Inclusion in the WHO Essential Medicines List facilitates procurement through international organizations and tender-based purchasing mechanisms, ensuring wider accessibility. The presence of seven buyers across two countries, as per our data, underscores a steady market opportunity for Bambuterol, particularly when aligned with national health priorities and procurement strategies.

Our analysis of Bambuterol imports from India between 2022 and 2026 reveals a buyer landscape primarily composed of pharmaceutical distributors. The top two buyers, MYIT MAHAR TRADING CO LTD and MYIT MAHAR TRADING CO., LTD., both based in Myanmar, collectively accounted for 100% of the total import value, amounting to $0.1 million. These entities are indicative of the distributor segment, which typically procures pharmaceuticals in bulk to supply to various healthcare providers, including hospitals, clinics, and pharmacies. Distributors often place large, periodic orders to maintain a steady supply chain and meet the consistent demand from healthcare facilities.

The remaining five buyers, while not individually identified in the provided data, are likely to fall into similar categories, given the nature of pharmaceutical imports. Hospital groups and retail chains may also be involved, procuring Bambuterol directly to ensure availability for patient treatment. Government procurement agencies, such as national health departments or entities like UNICEF, could be potential buyers, especially if Bambuterol is included in national treatment guidelines or essential medicines lists. These segments typically engage in tender-based purchasing, securing large quantities through competitive bidding processes to supply public healthcare institutions. Re-exporters and contract manufacturers are less likely in this context, as the data does not suggest onward export or local production activities related to Bambuterol.

Myanmar:

1. Drug Regulatory Authority Name: Food and Drug Administration (FDA) under the Ministry of Health.

2. Import Registration Process for Bambuterol: Importers must obtain an Import Recommendation from the FDA. All drugs, including Bambuterol, must be registered with the FDA. The registration process involves submitting a drug importation approval certificate, a drug wholesaler's license, and a drug registration certificate. Additionally, an import license from the Ministry of Commerce is required, which may necessitate recommendations from relevant government departments.

3. Estimated Timeline for Registration: The FDA aims to process import recommendations promptly; however, the exact timeline can vary. Import licenses are typically granted within 24 working hours, provided all documentation is in order.

4. Import Tariff/Duty for HS 30049099: The standard import tariff for pharmaceuticals under HS code 30049099 is 3%. However, certain essential medicines are exempt from customs tariffs. As of October 2022, 18 types of imported medicines were granted customs tariff exemption, but Bambuterol was not listed among them. (mdn.gov.mm)

Afghanistan:

1. Drug Regulatory Authority Name: Afghanistan National Medicines and Health Products Regulatory Authority (ANMHRA).

2. Import Registration Process for Bambuterol: Importers are required to register pharmaceuticals with the ANMHRA. The process includes submitting detailed product information, quality certifications, and compliance with national standards. An import license must be obtained, and the importer must hold a valid pharmaceutical business license.

3. Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and the ANMHRA's review procedures.

4. Import Tariff/Duty for HS 30049099: Specific import tariffs for pharmaceuticals under HS code 30049099 are not readily available. Importers should consult the Afghanistan Customs Department for the most current tariff information.

The demand for Bambuterol in Myanmar and Afghanistan is primarily driven by the prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization (WHO), approximately 235 million people worldwide suffer from asthma, with a significant burden in low- and middle-income countries. In Myanmar, Bambuterol is listed in the National List of Essential Medicines (NLEM) as of 2016, indicating its recognized importance in treating respiratory conditions. (platform.who.int)

Government healthcare programs and the expansion of universal health coverage in these countries also contribute to the demand for essential medicines like Bambuterol. Inclusion in the WHO Essential Medicines List facilitates procurement through international organizations and tender-based purchasing mechanisms, ensuring wider accessibility. The presence of seven buyers across two countries, as per our data, underscores a steady market opportunity for Bambuterol, particularly when aligned with national health priorities and procurement strategies.